Company
Sequenom
Last checked: Nov 19, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
0
510(k), De Novo and PMA
Device trials
6
As lead sponsor, any status
Adverse event reports
0
Received Nov 1, 2025 to Nov 19, 2026
Recall records
0
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
Not publicly listed. It has raised money in private placements reported to the SEC on Form D (filings through 2026Q3). A company with no recent filing may since have been acquired.
Total raised (reported)
$183M
4 Form D offerings, 2009 to 2015
Equity
$53.1M
Stock sold for cash
Debt and convertible notes
$130M
Loans and notes sold to investors
Last known valuation
Unknown
Form D filings do not report valuation
Latest round: convertible note, $85.0M raised of $85.0M sought, first sale Jun 9, 2015, 10 investors.
Funding rounds (Form D)
One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.
| First sale | Type | Raised | Round size | Investors | Exemption and agent | Filing |
|---|---|---|---|---|---|---|
| Jun 9, 2015 | Convertible note Issued in a merger or acquisition; not counted as money raised | $85.0M | $85.0M | 10 | Rule 506(b)Agent: Lazard Feres & Co.Commissions $1.5M | Form D ↗Jun 19, 2015 |
| Sep 17, 2012 | Debt | $130M | $130M | 2 | Rule 506 | Form D ↗Sep 24, 2012 |
| May 17, 2010 | Equity | $51.6M | $51.6M | 18 | Rule 506Agent: Lazard Capital Markets LLC, Jefferies & Company, Inc.Commissions $3.2M | Form D ↗May 24, 2010 |
| Dec 21, 2009 | Equity | $1.5M | $1.5M | 27 | Rule 506 | Form D ↗Dec 29, 2009 |
Company details
From the company's latest Form D.
- Legal name
- SEQUENOM INC
- Headquarters
- San Diego, United States
- Incorporated
- Delaware over five years before filing
- Entity type
- Corporation
- Revenue range
- Decline to Disclose
- Industry filed under
- Biotechnology
- SEC filer
- CIK 1076481 ↗
Executives, directors and promoters
As listed on the latest Form D.
- Richard LernerDirector
- Carolyn BeaverExecutive Officer
- Daniel GrosuExecutive Officer
- Myla Lai-GoldmanDirector
- John FazioDirector
- Charles SlacikDirector
- Kenneth BuechlerDirector
- William WelchExecutive Officer, Director
- David PendarvisDirector
- Dirk van den BoomExecutive Officer, Director
- Ronald LindsayDirector
- Robin WeinerExecutive Officer
- Jeff LintonExecutive Officer
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
No 5%+ shareholder filings or SBIR grants found under the name Sequenom.
Latest FDA decisions
No 510(k), De Novo or PMA decisions under this name since 2015.
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
NCT04595201 · 20,000 participants · Start Oct 13, 2020 · Primary completion Sep 1, 2026
Device: NIPT · For: Pregnancy
Sites: Westborough, Massachusetts
- Compliant Analysis of Patient Samples and DataEnrolling by invitation
NCT04364503 · 2,000 participants (planned) · Start Mar 17, 2018 · Primary completion Mar 17, 2030
Device: Multiple interventions depending on diagnostic test being run. · For: Pregnancy Related; Cancer; Infectious Disease
Sites: Los Angeles, California; San Diego, California; South San Francisco, California · 9 sites in all
NCT06008457 · 1,600 participants · Start Apr 17, 2023 · Primary completion May 31, 2025
Device: Labcorp COVID-19+Flu+RSV Test Home Collection Kit · For: COVID-19 Respiratory Infection; Influenza A; Influenza Type B and 1 more
Sites: Pasadena, California
NCT04774640 · 9 participants · Start May 29, 2014 · Primary completion Apr 30, 2018
Device: MaterniT GENOME · For: Copy Number Variations
Sites: New York, New York
NCT01597063 · 3,333 participants · Start Jul 2012 · Primary completion Feb 2014
Device: SEQureDx Trisomy Test · For: Aneuploidy; Down Syndrome; Noninvasive Prenatal Screening
Sites: Mobile, Alabama; Chandler, Arizona; Phoenix, Arizona · 27 sites in all
NCT01650948 · 100 participants · Start Jul 2012 · Primary completion Dec 2013
Device: RetnaGene AMD LDT · For: Age-related Macular Degeneration
Sites: San Francisco, California; Lexington, Kentucky; Nashville, Tennessee
Reports received
0
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
0
Injury reports
0
Death reports
0
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
No reports to chart for this view.
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
No device types to rank.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
No brand names to rank.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recalls under this name in FDA's data.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.